Competitive advantages by "Choice and Concentration Strategy" tailored to the corporate development stages
Unlike other conventional biotech companies, DuChemBio has achieved a consolidated growth based on solid sales.
After securing cutting-edge manufacturing facilities and competent human resources,
DuChemBio has completed its own peculiar business scheme. It is expected to realize high profit from 2020.
※ Launching schedules for new drugs
FESSecond half of 2020
177Lu-DOTATOCFirst half of 2021
FACBCSecond half of 2021
Contact firstname.lastname@example.org to get more information